InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794

Reuters10-31

InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794

InnoCare Pharma Ltd. has announced the dosing of the first patient in a clinical trial of its novel B7-H3 targeted antibody-drug conjugate $(ADC)$, ICP-B794, in China. ICP-B794 is developed from InnoCare's proprietary ADC platform and consists of a humanized anti-B7-H3 monoclonal antibody conjugated to an in-house developed payload via a protease-cleavable linker. The therapy is designed to precisely target tumor cells while minimizing off-target effects and is being evaluated for the treatment of various solid tumors, including lung, esophageal, nasopharyngeal, head and neck, and prostate cancers. Preclinical studies have shown superior anti-tumor activity and significant tumor-killing effects compared to other ADCs. According to the announcement, there are currently no B7-H3 targeted therapies approved for marketing globally. The results of this clinical trial have not yet been presented and will be made available in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565895-en) on October 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579488863?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 08:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579488863","market":"us","top_or_hot":-1,"title":"InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InnoCare Pharma Ltd. has announced the dosing of the first patient in a clinical trial of its novel B7-H3 targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, ICP-B794, in China. ICP-B794 is developed from InnoCare's proprietary ADC platform and consists of a humanized anti-B7-H3 monoclonal antibody conjugated to an in-house developed payload via a protease-cleavable linker. The therapy is designed to precisely target tumor cells while minimizing off-target effects and is being evaluated for the treatment of various solid tumors, including lung, esophageal, nasopharyngeal, head and neck, and prostate cancers. Preclinical studies have shown superior anti-tumor activity and significant tumor-killing effects compared to other ADCs. According to the announcement, there are currently no B7-H3 targeted therapies approved for marketing globally. The results of this clinical trial have not yet been presented and will be made available in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565895-en) on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 08:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        InnoCare Pharma Ltd. has announced the dosing of the first patient in a clinical trial of its novel B7-H3 targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, ICP-B794, in China. ICP-B794 is developed from InnoCare's proprietary ADC platform and consists of a humanized anti-B7-H3 monoclonal antibody conjugated to an in-house developed payload via a protease-cleavable linker. The therapy is designed to precisely target tumor cells while minimizing off-target effects and is being evaluated for the treatment of various solid tumors, including lung, esophageal, nasopharyngeal, head and neck, and prostate cancers. Preclinical studies have shown superior anti-tumor activity and significant tumor-killing effects compared to other ADCs. According to the announcement, there are currently no B7-H3 targeted therapies approved for marketing globally. The results of this clinical trial have not yet been presented and will be made available in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565895-en) on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL67vD6G:1","article_id":"2579488863","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579488863","pubTimestamp":1761870612,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"InnoCare Pharma Ltd. has announced the dosing of the first patient in a clinical trial of its novel B7-H3 targeted antibody-drug conjugate , ICP-B794, in China. ICP-B794 is developed from InnoCare's proprietary ADC platform and consists of a humanized anti-B7-H3 monoclonal antibody conjugated to an in-house developed payload via a protease-cleavable linker. The therapy is designed to precisely target tumor cells while minimizing off-target effects and is being evaluated for the treatment of various solid tumors, including lung, esophageal, nasopharyngeal, head and neck, and prostate cancers. Preclinical studies have shown superior anti-tumor activity and significant tumor-killing effects compared to other ADCs. According to the announcement, there are currently no B7-H3 targeted therapies approved for marketing globally. The results of this clinical trial have not yet been presented and will be made available in the future.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK0239":"医药制造","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"诺诚健华医药在新型B7-H3 ADC ICP-B794临床试验中为首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":0.9,"NDAQ":0.9},"content_text":"InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794\n    \n\n        InnoCare Pharma Ltd. has announced the dosing of the first patient in a clinical trial of its novel B7-H3 targeted antibody-drug conjugate $(ADC)$, ICP-B794, in China. ICP-B794 is developed from InnoCare's proprietary ADC platform and consists of a humanized anti-B7-H3 monoclonal antibody conjugated to an in-house developed payload via a protease-cleavable linker. The therapy is designed to precisely target tumor cells while minimizing off-target effects and is being evaluated for the treatment of various solid tumors, including lung, esophageal, nasopharyngeal, head and neck, and prostate cancers. Preclinical studies have shown superior anti-tumor activity and significant tumor-killing effects compared to other ADCs. According to the announcement, there are currently no B7-H3 targeted therapies approved for marketing globally. The results of this clinical trial have not yet been presented and will be made available in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565895-en) on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579488863","isCrawlerRequest":true}